• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.290 +0.090 (+7.50%)
Official Closing Price Updated: 4:10 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Today 9:45 EDT
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Lineage Cell Therapeutics Q1 Earnings Call Highlights ↗
May 15, 2026
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program... 
Via MarketBeat
Topics Earnings
Lineage Cell Therapeutics (NYSEARCA:LCTX) Q1 2026 Results: Revenue Miss and Increased Losses Weigh on Investor Sentiment ↗
May 12, 2026
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss ↗
March 05, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
 
Via Benzinga
News headline image
A Peek at Lineage Cell Therapeutics's Future Earnings ↗
August 11, 2025
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
May 05, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
May 04, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Formation of Scientific Advisory Board
April 13, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
March 24, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 05, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
February 26, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Issues Letter to Stockholders
January 05, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
January 06, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
November 06, 2025
Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027. 
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
October 30, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
September 22, 2025
 
Via Benzinga
News headline image
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
September 08, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗
August 27, 2025
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
September 02, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
August 26, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
August 15, 2025
 
Via Benzinga
News headline image
Lineage Cell Revenue Doubles in Q2 ↗
August 12, 2025
Via The Motley Fool
News headline image
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗
August 12, 2025
Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027. 
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
August 12, 2025
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
August 05, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
August 04, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap